Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency Among Children in Eastern Saudi Arabia

Muneer H Albagshi1, Suad Alomran2, Somaya Sloma2

  • 1Department of Pediatric Hematology, Hereditary Blood Diseases Center, Al-Ahsa, SAU.

Cureus
|December 3, 2020
PubMed

Insights

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is highly prevalent in Saudi Arabia, affecting 25% of children screened. Implementing newborn screening for G6PD deficiency is crucial to prevent severe health issues like jaundice and hemolytic anemia.

Area of Science:

  • Medical Genetics
  • Hematology
  • Public Health

Background:

  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common red blood cell enzyme disorder globally.
  • It predominantly affects males due to its X-linked recessive inheritance pattern.
  • Saudi Arabia lacks a newborn screening program for G6PD deficiency despite documented high prevalence.

Purpose of the Study:

  • To determine the prevalence of G6PD deficiency in children aged 0-14 years in Saudi Arabia.
  • To assess the prevalence of G6PD deficiency in newborns within the study population.
  • To highlight the need for establishing a national newborn screening program.

Main Methods:

  • A 10-year retrospective study (2008-2017) analyzing hospitalization data.
  • Screening of 48,889 children (0-14 years) using a qualitative fluorescence test.
  • Specific analysis of 25,628 newborns within the screened population.

Main Results:

  • Overall G6PD deficiency prevalence was 25% in children aged 0-14 years.
  • Prevalence was significantly higher in males (33.8%) compared to females (13.2%).
  • Newborns showed an 18.8% prevalence, with males at 26% and females at 9.9%.

Conclusions:

  • The study confirms a high prevalence of G6PD deficiency in the Saudi community.
  • Establishing a newborn screening program is recommended to prevent neonatal hyperbilirubinemia and hemolytic episodes.
  • Increased awareness among healthcare practitioners regarding G6PD deficiency is essential.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
562
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
26.7K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.6K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.9K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
92
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
619